#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Usher's syndrome Ependymoma Philadelphia positive acute lymphocytic leukaemia Cholangiocarcinoma Proteus syndrome Neuronal ceroid lipofuscinosis Cardiac sarcoidosis Biliary cancer metastatic Choroid melanoma SAPHO syndrome Partial lipodystrophy Rhabdomyosarcoma recurrent Neovascular age-related macular degeneration Albright's disease Wiskott-Aldrich syndrome More trials…

    Learn about Rare Diseases

    Lymphangiosarcoma – Trials in Disease Rett syndrome – Life with Disease Optic glioma – Treatment Mantle cell lymphoma refractory – Diagnostics Amyotrophic lateral sclerosis – Basic Information Piriformis syndrome – Diagnostics Sjogren’s syndrome – Treatment Glycogen storage disease type II Phenylketonuria – Treatment Acquired haemophilia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-LEUCINE Botaretigene Sparoparvovec Navitoclax Ibuprofen Lysine Folic Acid, Anhydrous Chlorhexidine Gluconate Phentermine Exidavnemab Ramipril Tenecteplase Ruxolitinib Indacaterol Maleate Octocog Alfa Gindameran Magnesium Stearate Etravirine Ianalumab Zibotentan Enfuvirtide Midazolam Hydrochloride More therapies…

    Learn about Your Condition

    Urticaria Incontinence Pterygium Endometrial cancer stage II Urea cycle disorder Retinal artery occlusion Thromboangiitis obliterans Ewing's sarcoma metastatic Arteriovenous graft thrombosis Malignant lymphoid neoplasm Metastases to meninges Hypothyroidism Haemodialysis Acute myocardial infarction Chronic hepatitis C More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm

  • Study of DCC-3084 alone and with other cancer drugs in patients with advanced solid tumors driven by the MAPK pathway

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • DCC-3084
    France Germany Spain

  • Study on the Safety and Effects of GSK4418959 and Dostarlimab for Adults with Colorectal Cancer with Mismatch Repair Deficiency or High Microsatellite Instability

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    • Neoplasm
    Investigated Drugs:
    • GSK4418959A
    • Dostarlimab
    Belgium The Netherlands Spain

  • Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    • Niraparib
    France

  • Study on the Safety and Effects of RP-1664 for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Rp-1664 Sulfate
    Denmark

  • Study on ANV600 and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Anv600
    • Pembrolizumab
    Belgium France Germany The Netherlands Spain

  • Study of RVU120 for Patients with Advanced Solid Tumors After Standard Treatments Have Failed

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    Poland Spain
Previous Page
1 … 13 14 15 16 17 … 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!